Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, May 18, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Nierengarten Reiterated (TSVT) at Buy and Held Target at $26 on, May 18th, 2023
David Nierengarten of Wedbush, Reiterated "2seventy bio, Inc." (TSVT) at Buy and Held Target at $26 on, May 18th, 2023.
David has made no other calls on TSVT in the last 4 months.
There are 2 other peers that have a rating on TSVT. Out of the 2 peers that are also analyzing TSVT, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $28 on, Tuesday, January 24th, 2023
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $28 on, Friday, January 20th, 2023
